Greenwich LifeSciences annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Greenwich LifeSciences R&D Spending Growth & History (GLSI)
Greenwich LifeSciences's r&d spending was $17.2M for fiscal 2025.
View full Greenwich LifeSciences company overviewGreenwich LifeSciences annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $17.2M | $1.7M | +11.24% |
| 2024 | 2024-12-31 | $15.5M | $7.8M | +101.08% |
| 2023 | 2023-12-31 | $7.7M | $1.2M | +18.89% |
| 2022 | 2022-12-31 | $6.5M | $2.9M | +81.93% |
| 2021 | 2021-12-31 | $3.6M | $2.5M | +236.56% |
| 2020 | 2020-12-31 | $1.1M | −$1.5M | −59.42% |
| 2019 | 2019-12-31 | $2.6M | — | — |
Greenwich LifeSciences quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.6M | $142,237 | +4.16% |
| Q1 2026 | 2026-03-31 | $5.2M | $2.9M | +129.29% |
| Q4 2025 | 2025-12-31 | $8.3M | −$420,155 | −4.84% |
| Q3 2025 | 2025-09-30 | $3.3M | $975,100 | +42.54% |
| Q2 2025 | 2025-06-30 | $3.4M | $1.1M | +48.04% |
| Q1 2025 | 2025-03-31 | $2.3M | $76,635 | +3.49% |
| Q4 2024 | 2024-12-31 | $8.7M | $6.4M | +272.30% |
| Q3 2024 | 2024-09-30 | $2.3M | $133,873 | +6.20% |
| Q2 2024 | 2024-06-30 | $2.3M | $928,306 | +67.29% |
| Q1 2024 | 2024-03-31 | $2.2M | $366,606 | +20.06% |
| Q4 2023 | 2023-12-31 | $2.3M | −$125,123 | −5.09% |
| Q3 2023 | 2023-09-30 | $2.2M | $434,674 | +25.22% |
| Q2 2023 | 2023-06-30 | $1.4M | $746,317 | +117.86% |
| Q1 2023 | 2023-03-31 | $1.8M | $167,086 | +10.06% |
| Q4 2022 | 2022-12-31 | $2.5M | $394,196 | +19.10% |
| Q3 2022 | 2022-09-30 | $1.7M | $1.1M | +162.29% |
| Q2 2022 | 2022-06-30 | $633,250 | $76,716 | +13.78% |
| Q1 2022 | 2022-03-31 | $1.7M | $1.4M | +488.99% |
| Q4 2021 | 2021-12-31 | $2.1M | $1.5M | +244.63% |
| Q3 2021 | 2021-09-30 | $657,096 | $499,065 | +315.80% |
| Q2 2021 | 2021-06-30 | $556,534 | $405,730 | +269.04% |
| Q1 2021 | 2021-03-31 | $281,977 | $132,086 | +88.12% |
| Q4 2020 | 2020-12-31 | $598,880 | — | — |
| Q3 2020 | 2020-09-30 | $158,031 | −$126,473 | −44.45% |
| Q2 2020 | 2020-06-30 | $150,804 | — | — |
| Q1 2020 | 2020-03-31 | $149,891 | — | — |
| Q3 2019 | 2019-09-30 | $284,504 | — | — |
Greenwich LifeSciences r&d spending trends
Over the last five fiscal years, Greenwich LifeSciences's r&d spending increased from $1.1M to $17.2M, a change of $16.2M. The latest reported quarter, Q2 2026, shows $3.6M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Greenwich LifeSciences source filings ↗